Clemency Jolly

Clemency Jolly

Auto-generated profile, based on publicly available information

Clemency Jolly

The Francis Crick Institute NW1 1AT London United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMoritz Gerstung
Moritz Gerstung
CJClemency Jolly
Clemency Jolly
ILIgnaty Leshchiner
Ignaty Leshchiner
SDStefan C. Dentro
Stefan C. Dentro
SGSantiago Gonzalez
Santiago Gonzalez
HGHeterogeneity Working Group
Heterogeneity Working Group
Summary: Cancer develops through a process of somatic evolution. Here, we use whole-genome sequencing of 2,778 tumour samples from 2,658 donors to reconstruct the life history, evolution of mutational processes, and driver mutation sequences of 39 cancer types. The early phases of oncogenesis are driven by point mutations in a small set of driver genes, often including biallelic inactivation of tumour suppressors. Early oncogenesis is also characterised by specific copy number gains, such as trisomy 7 in glioblastoma or isochromosome 17q in medulloblastoma. By contrast, increased genomic instability, a nearly four-fold diversification of driver genes, and an acceleration of point mutation processes are features of later stages. Copy-number alterations often occur in mitotic crises leading to simultaneous gains of multiple chromosomal segments. Timing analysis suggests that driver mutations often precede diagnosis by many years, and in some cases decades, providing a window of opportunity for early cancer detection.

5 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
SDStefan C. Dentro
Stefan C. Dentro
ILIgnaty Leshchiner
Ignaty Leshchiner
KHKerstin Haase
Kerstin Haase
MTMaxime Tarabichi
Maxime Tarabichi
JWJeff Wintersinger
Jeff Wintersinger
HCHeterogeneity Working Groupthe PCAWG consortium.
Heterogeneity Working Groupthe PCAWG consortium.
SUMMARY: Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. To address this question, we extensively characterize ITH across whole-genome sequences of 2,658 cancer samples, spanning 38 cancer types. Nearly all informative samples (95.1%) contain evidence of distinct subclonal expansions, with frequent branching relationships between subclones. We observe positive selection of subclonal driver mutations across most cancer types, and identify cancer type specific subclonal patterns of driver gene mutations, fusions, structural variants and copy-number alterations, as well as dynamic changes in mutational processes between subclonal expansions. Our results underline the importance of ITH and its drivers in tumor evolution, and provide an unprecedented pan-cancer resource of comprehensively annotated subclonal events from whole-genome sequencing data.